Burning Rock Biotech Ltd: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Apr 28, 2026 and accepted by EDGAR at Apr 28, 2026, 06:08 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $77.2m | us-gaap:Revenues |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $19.5m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $57.6m | us-gaap:GrossProfit |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $23.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$7.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $223.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$7.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$4.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $751.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $68.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $105.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $117.3m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $35.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $40.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $76.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-26-183377. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.